Silo Pharma Expands Into AI With Qwikagents Asset Acquisition

Silo Pharma Inc. (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following the acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The move positions the company to capitalize on a rapidly growing AI agent market projected to reach $47 billion to $53 billion by 2030, according to the press release.

The company will continue advancing its SPC-15 PTSD program toward an investigational new drug application submission and Phase 1 clinical trials, underscoring a dual focus on biopharmaceutical development and emerging AI-driven revenue opportunities. Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, with a therapeutic focus on addressing underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis.

The acquisition of Qwikagents.ai assets allows Silo to enter the AI agent space, which is expected to see significant growth in the coming years. Autonomous AI agents are increasingly used across industries for tasks that require minimal human intervention. For more details on the acquisition, the full press release is available at https://ibn.fm/XJG64.

Silo Pharma’s research is conducted in collaboration with leading universities and laboratories. The company’s latest news and updates are available in its newsroom at https://ibn.fm/SILO. This expansion into AI represents a strategic diversification for Silo, allowing it to leverage its expertise in technology while maintaining its core biopharmaceutical pipeline.